FINWIRES · TerminalLIVE
FINWIRES

$DRTS

5 stories mentioning DRTSUpdated 14d ago

Every FINWIRES story that references DRTS, newest first.

Insider Trading

Alpha Tau Medical Insider Sold Shares Worth $352,115, According to a Recent SEC Filing

Raphi Levy, Chief Financial Officer, on June 03, 2026, sold 32,500 shares in Alpha Tau Medical (DRTS) for $352,115. Following the Form 4 filing with the SEC, Levy has control over a total of 147,680 ordinary shares of the company, with 147,680 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1871321/000121390026065201/xslF345X05/marketforms-73357.xmlPrice: $10.29, Change: $-0.29, Percent Change: -2.74%

$DRTS
Wire

Alpha Tau Medical, Tolmar International Agree to Develop, Commercialize Prostate Cancer Therapy

Alpha Tau Medical (DRTS) and Tolmar International have agreed to develop and commercialize Alpha DaRT therapy for the treatment of prostate cancer in the US, the companies said Wednesday.Under the agreement, Alpha Tau will lead clinical development and manufacture the therapy, while Tolmar International will receive exclusive rights it in the US, according to the companies.Additionally, the companies said Tolmar International will make a $20 million equity investment in Alpha Tau at $11.99 per share and provide $15 million towards a new US manufacturing facility.The deal also includes up to $96.5 million in development and regulatory milestones and up to $65 million in commercial milestone payments for the initial indication, Alpha Tau Medical and Tolmar International said.Alpha Tau said it will sell Alpha DaRT to Tolmar at 60% of onward net sales price, subject to certain adjustments.Alpha Tau Medical shares were over 15% higher in early Wednesday trading.Price: $10.31, Change: $+1.38, Percent Change: +15.45%

$DRTS
Wire

Alpha Tau Medical Reports Data Showing Alpha DaRT Increases Overall Survival for Patients With Pancreatic Cancer

Alpha Tau Medical (DRTS) said Monday that data from a pooled analysis of three prospective phase 1/2 trials of its Alpha DaRT device to treat advanced pancreatic cancer, exceeded the overall survival and safety rate compared with standard second-line chemotherapy.The oncology company said the data came from a pooled analysis of the clinical studies, which are evaluating endoscopic ultrasound-guided intratumoral Alpha DaRT treatment in patients who have locally advanced or metastatic pancreatic ductal adenocarcinoma.Alpha DaRT-treated patients who have already received two lines of chemotherapy had a median overall survival of 17.1 months in locally advanced disease, and 11.3 months in metastatic disease, the company said. This is compared with approximately nine months for and four to six months respectively for standard second-line chemotherapies, Alpha Tau Medical said.Price: $10.52, Change: $-0.31, Percent Change: -2.86%

$DRTS
Wire

Alpha Tau Says Complete Response in 2 Brain Cancer Patients Observed in Interim Trial of Radiation Treatment

Alpha Tau Medical (DRTS) said Monday it released interim data from a US clinical trial evaluating its radiation treatment in three patients with a recurrent form of brain cancer.Two participants achieved a complete response with the disappearance of tumor lesions, while the third showed a 30% reduction in tumor size, the company said.The safety review noted one serious adverse event involving a seizure and temporary paralysis that was subsequently resolved with steroids, it said.Shares of the company were up over 20% in Monday premarket activity.Price: $10.25, Change: $+1.74, Percent Change: +20.48%

$DRTS
Wire

Alpha Tau Expands Alpha Dart Trial Following FDA Approval of IDE Supplement

Alpha Tau Medical (DRTS) said Thursday that the US Food and Drug Administration has approved an Investigational Device Exemption, or IDE, supplement for its pancreatic cancer study.The IDE supplement expands the Impact pancreatic cancer trial to allow ten additional newly diagnosed patients receiving gemcitabine/nab-paclitaxel together with Alpha DaRT, taking the total number of recruits for the study to 40 patients, the company said.The Impact study is evaluating the safety, feasibility, and efficacy of Alpha DaRT, in combination with chemotherapy for patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma, Alpha Tau Medical said.Price: $8.11, Change: $+0.03, Percent Change: +0.37%

$DRTS

Track with the FINWIRES app suite

FolioX
FolioX
Track DRTS in your portfolio
WheelAI
WheelAI
Analyze DRTS options with the wheel strategy
StockInsider
StockInsider
See market sentiment on DRTS